Mostrando 5 resultados de: 5
Filtros aplicados
Publisher
BMC Cancer(1)
Cancer Immunology, Immunotherapy(1)
Frontiers in Immunology(1)
Frontiers in Oncology(1)
Seminars in Oncology(1)
Área temáticas
Enfermedades(5)
Farmacología y terapéutica(3)
Ginecología, obstetricia, pediatría, geriatría(1)
Área de conocimiento
Inmunología(2)
Objetivos de Desarrollo Sostenible
ODS 10: Reducción de las desigualdades(5)
ODS 3: Salud y bienestar(5)
ODS 17: Alianzas para lograr los objetivos(4)
ODS 9: Industria, innovación e infraestructura(1)
Origen
scopus(5)
Associations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer
ArticleAbstract: Aging is considered the single most significant risk factor for the majority of common malignances iPalabras claves:B cells, Epidermal growth factor, Pro-inflammatory cytokines, T cells, terminally differentiated T cellsAutores:Añe-Kouri A.L., Catala M., Cordero L., García Verdecia B., González A., Lage Davila A., Ledón N., Luaces P.L.o., Mazorra Z., Neninger Vinageras E., Pereira K., Saavedra Hernández D., Salomón E.E., Sánchez M.G., Suárez G.M., Tania CrombetFuentes:scopusAugmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC
ArticleAbstract: Background: CIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy which has shownPalabras claves:immune checkpoint inhibitor, immunotherapy, lung cancer, Non-small cell lung cancer, VaccineAutores:Attwood K., Cedeno C., Cinquino A., Dai T., Dozier A., Dy G.K., Ernstoff M., Evans R., Fisher D.T., Fountzilas C., Groman A., Hutson A., Johnson C., Lage Davila A., Lee K., Leon K., Luaces P.L.o., Mazorra Z., Mesa C., Muhitch J., Opyrchal M., Puzanov I., Reid M., Saavedra Hernández D., Santos-Morales O., Tania Crombet, Wallace P.K.Fuentes:scopusCIMAvax-EGF: A new therapeutic vaccine for advanced non-small cell lung cancer patients
ReviewAbstract: Lung cancer is the common fatal illness with the highest incidence and mortality globally. EpidermalPalabras claves:cancer vaccine, CIMAvax-EGF, Clinical trial, immunotherapy, Non-small cell lung cancerAutores:Saavedra Hernández D., Tania CrombetFuentes:scopusCIMAvax-EGF: Toward long-term survival of advanced NSCLC
ReviewAbstract: Lung cancer remains one of the leading causes of cancer-related deaths. Non–small cell lung cancer (Palabras claves:cancer vaccine, CIMAvax-EGF, Clinical trial, EGF, Epidermal growth factor receptor, immunotherapy, non–small cell lung cancerAutores:Camilo Rodríguez, Carmen Elena Viada, Lage Davila A., Mazorra Z., Neninger Vinageras E., Saavedra Hernández D., Tania CrombetFuentes:scopusIdentifying predictive biomarkers of CIMAvaxEGF success in non-small cell lung cancer patients
ArticleAbstract: Background: Immunosenescence biomarkers and peripheral blood parameters are evaluated separately asPalabras claves:Causal inference, CIMAvaxEGF, Non-small-cell lung cancer, Pbkp_redictive biomarkersAutores:Alonso A., Lage Davila A., Luaces P.L.o., Molenberghs G., Saavedra Hernández D., Sánchez L., Tania Crombet, Van der Elst W.Fuentes:scopus